News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Orgenics Announces a Second Phase 1 Clinical Trial of SMaRT(TM) Replacement Therapy



1/31/2011 9:33:13 AM

TAMPA, Fla.--(BUSINESS WIRE)--Florida-based biopharmaceutical company Oragenics, Inc. (OTCBB: ORNI) (www.oragenics.com) today announced its intention to commence a second phase 1 clinical trial of SMaRT Replacement Therapy. The Company has retained PRA International as the Clinical Research Organization (CRO) for clinical trials management services related to the second Phase 1 clinical trial of SMaRT, which is currently set to begin in the first quarter of 2011 at PRA International’s Lenexa, Kansas, clinical facility.

Read at BioSpace.com


comments powered by Disqus
Orgenics
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES